By Matthew Pillar, Editor, Bioprocess Online
From my perch in the Business of Biotech podcast studio, I’ve interviewed quite a few biopharma leaders whose careers were inspired by very personal experiences with disease.
Ray Therapeutics CEO Paul Bresge is one such leader. Until 2010, leading a biotech wasn’t on his radar. He’d built a long and successful career as a leader in unrelated industries - industrial tools and a courier service, for example. Then, his 15-year-old daughter was diagnosed with retinitis pigmentosa (RP), a rare genetic disease that causes degradation of retinal cells over time. She was going blind. Ophthalmologists told him there was nothing that could be done to save his daughter’s vision.